Detalles de la búsqueda
1.
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
N Engl J Med
; 378(18): 1671-1680, 2018 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29668352
2.
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
Am J Respir Crit Care Med
; 202(9): 1237-1243, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32584168
3.
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
; 201(12): 1508-1516, 2020 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162970
4.
The effect of exacerbation history on outcomes in the IMPACT trial.
Eur Respir J
; 55(5)2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32299860
5.
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Respir Res
; 21(1): 139, 2020 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32503599
6.
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.
Eur Respir J
; 58(3)2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34385263
7.
Misinterpretation of time-to-first event curves can lead to inappropriate treatment.
Eur Respir J
; 54(3)2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31488584
8.
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Chest
; 159(3): 985-995, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33031829
9.
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.
Pulm Ther
; 7(1): 101-118, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33201438
10.
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
Ann Am Thorac Soc
; 18(5): 788-798, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33108212
11.
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Chronic Obstr Pulm Dis
; 8(1)2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33156982
12.
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Ther Adv Respir Dis
; 14: 1753466620963021, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33121372
13.
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Adv Ther
; 37(9): 3775-3790, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32647911
14.
The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Int J Chron Obstruct Pulmon Dis
; 14: 2849-2861, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31839705
15.
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Adv Ther
; 39(3): 1446, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35060093
Resultados
1 -
15
de 15
1
Próxima >
>>